New drug cocktail aims to control rare blood cancer without chemo
NCT ID NCT03863184
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of three drugs—acalabrutinib, lenalidomide, and either rituximab or obinutuzumab—in people with untreated mantle cell lymphoma. The goal is to see how well the combo clears cancer cells from the blood and shrinks tumors. Participants receive the drugs for about a year, then continue on a maintenance schedule until the disease worsens or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib, lenalidomide, and rituximab or obinutuzumab
What this could lead to
If successful, this combination could offer a more effective first-line treatment for mantle cell lymphoma, potentially leading to longer remission without the need for chemotherapy.
What could go wrong
This is a small, early-phase study (37 people) without a comparison group. The drugs have known side effects like low blood counts, infections, and fatigue. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medicine
New York, New York, 10065, United States